Abstract IA04: Regulation of the Hippo pathway in cancer
Abstract
Abstract The Hippo pathway is crucial in organ size control and its dysregulation contributes to tumorigenesis. Core components of the Hippo pathway include the protein kinases of MST1/2, MAP4Ks, LATS1/2, the transcription co-activators YAP/TAZ, and their DNA binding partners TEADs. LATS phosphorylates YAP/TAZ to promote cytoplasmic localization and degradation, thereby inhibiting YAP/TAZ and cell growth. The Hippo pathway is regulated by a wide range of signals, including cell density, GPCR, cellular energy levels, and mechanical cues. We will present our recent progresses on Hippo pathway regulation and its role in cancer. The emerging role of the Hippo pathway in tumorigenesis suggests the potential therapeutic value of targeting this pathway for cancer treatment. Citation Format: Kun-Liang Guan. Regulation of the Hippo pathway in cancer [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr IA04.
Related Papers
- → Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling(2013)102 cited
- → Roles of mammalian sterile 20‐like kinase 2‐dependent phosphorylations of Mps one binder 1B in the activation of nuclear Dbf2‐related kinases(2009)21 cited
- → c-Myc transactivation domain-associated kinases: Questionable role for map kinases in c-Myc phosphorylation(1999)26 cited
- → The Hippo–YAP pathway in organ size control and tumorigenesis: an updated version(2010)1,133 cited